Scalper1 News
Regeneron (REGN) said an experimental drug it’s developing with Sanofi (SNY) was found in a late-stage trial to be effective in fighting “bad” cholesterol, even when injected once every four weeks instead of two weeks. The report makes the drug, alirocumab, easier for people with high cholesterol to take, increasing the likelihood consumers will prefer it. The drug is expected to hit the market in the third quarter of this year. Alirocumab is in a Scalper1 News
Scalper1 News